menu
    • menu

    Company profile for Amunix

    Sanofi-PSE
    News
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California

    11 Apr 2024

    // Ayisha Sharma ENDPTS

    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors

    23 Jun 2021

    // GLOBENEWSWIRE

    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)

    13 Apr 2021

    // GLOBNEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Sanofi

    Contact Supplier

    Website

    American Pharma Summit

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity. We address this challenge by using our universal, protease-releasable masking technology (Pro-XTEN), to create next generation, conditionally active TCEs (XPATs®) and cytokines (XPACs)

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmunixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Tower Pl #1100, South San Francisco, CA 94080 650-428-1800
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amunix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amunix/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Top Pharma Companies & Drugs in 2021: Covid vaccines, pills cause churn in list

    Top Pharma Companies & Drugs in 2021: Covid vaccines, pills cause churn in list

    Every year, the list of top pharmaceutical products and companies by sales sees some churn. But the year 2021 was a lot different — it saw the pharma industry landscape change dramatically. It was a year when the industry was busy developing vaccines and therapies so that the world could recover from the Covid-19 pandemic. And this resulted in many drugmakers raking in billions of dollars in sales. As a result, the top company of 2020 in terms of pharmaceutical sales — Roche — slipped to the number five spot, while Pfizer, which was at number eight in 2020 after spinning off its generic business, moved up to the number one slot. The year proved to be a good one for pharmaceutical companies. Interestingly, last year none of the top 20 pharmaceutical companies saw a decline in their revenue. View Our Interactive Dashboard on Top Drugs by Sales in 2021 (Free Excel Available) Pfizer’s Comirnaty steals the show The company that reaped the maximum gains from its Covid vaccine was Pfizer. Comirnaty (tozinameran) was the top selling pharmaceutical product of 2021, posting global revenues of US$ 36.8 billion. This messenger-RNA Covid-19 vaccine, developed along with its German partner BioNTech, catapulted Pfizer to the slot of the top company by sales in 2021. Pfizer’s global topline grew from US$ 41.7 billion in 2020 to US$ 81.3 billion in 2021.  In 2020, Pfizer was at number eight, behind Roche, Novartis, GSK, AbbVie, J&J, Merck and BMS. In 2021, it took a lead of billions of dollars on all these companies. The second largest drug company by sales — AbbVie — was way down at US$ 56.1 billion in global revenues. In fact, Comirnaty has become the fastest-selling drug in the history of the pharmaceutical industry. Back in December 2020, when both Comirnaty and Moderna’s Spikevax had bagged the US Food and Drug Administration’s emergency use authorization (EUA), there was a lot of uncertainty around how the promised doses would be delivered across the world. But both Comirnaty and Spikevax have proven to be a resounding success. Spikevax emerged as the third largest selling pharmaceutical product of 2021, bringing in US$ 17.7 billion for Moderna. Analysts expect both Pfizer-BioNTech and Moderna to sell even more vaccines in 2022. The reasons are manifold. First, SARS-CoV-2 is able to mutate often, and is unlikely to be eradicated in the near future, creating a need for booster shots. Second, the younger age groups are still to get vaccinated. Along with Comirnaty, Pfizer is battling Covid-19 with its antiviral pill, Paxlovid. Though the sales of Paxlovid have nosedived of late, Pfizer expects Comirnaty and Paxlovid to help the New York-headquartered drug behemoth achieve US$ 100 billion in 2022 revenues. View Our Interactive Dashboard on Top Drugs by Sales in 2021 (Free Excel Available) AbbVie moves up, sans Covid product; Roche slips to number five With no Covid-19 related products, AbbVie did fairly well in 2021 — it moved up from the number four spot in 2020 to number two position, thanks to its Allergan acquisition, cash cow Humira (adalimumab), the continued success of its cancer drug Imbruvica (ibrutinib) and an increase in sale of its psoriasis treatment Skyrizi (risankizumab) by a whopping 85 percent in 2021. Humira brought in sales of US$ 21.2 billion for AbbVie in 2021. However, things may change soon, with biosimilars of Humira slated to enter the market in 2023. The years 2022 and 2023 are likely to be transition years for AbbVie, as it works to build the market for its Humira successors — Rinvoq and Skyrizi. Roche emerged as a big loser in 2021, as several copycats of its blockbuster drugs hit the market. Copycats to Roche’s three blockbuster cancer drugs—Avastin, Herceptin and Rituxan—eroded US$ 4.9 billion (CHF 4.73 billion) from the company’s sales in 2021. A large chunk of growth for Roche came from its multiple sclerosis med Ocrevus, hemophilia drug Hemlibra, inflammatory disease therapy Actemra and PD-L1 inhibitor Tecentriq. The pandemic resulted in lower-than-expected sales of Ocrevus (ocrelizumab) due to fears around its immunosuppressive effects. Like Roche, Novartis also slipped last year. It fell from number two in 2020 to the number four slot in 2021. Essentially, Novartis is struggling with a relatively lackluster pipeline. It had sold its 33 percent stake in Roche last year for US$ 20.7 billion. It plans to use that sum for acquisitions in order to beef up its pipeline. The Swiss drugmaker has also drawn up a restructuring plan that includes layoffs of thousands of employees. Before the pandemic, Merck’s Keytruda was touted as the drug that would overtake Humira at the top in 2024. The checkpoint inhibitor has continued to grow impressively, adding new indications and treatment lines. Keytruda is now used in close to 40 indications. With US$ 17.2 billion in sales, Keytruda emerged as the fourth largest selling drug of 2022. Overall though, Merck slipped from number six to the number eight slot. This was due to the fact that Merck had spun out its women’s health, biosimilars and established brands businesses into Organon. However, its Covid-19 antiviral pill — Molnupiravir — was able to compensate for the lost revenue. Though the FDA is yet to grant the drug a full approval (it bagged an EUA in December 2021), advance sales agreements helped it rack up US$ 952 million in sales in the fourth quarter. View Our Interactive Dashboard on Top Drugs by Sales in 2021 (Free Excel Available) BMS moves up with Eliquis, Revlimid; J&J lands at number three Bristol Myers Squibb (BMS) moved up from number seven in 2020 to number six, thanks to two of its drugs that made it to top 10 — anticoagulant Eliquis at number five and oncology drug Revlimid at number six. However, Revlimid will soon face competition — four generic companies now have the approval to sell their versions of Revlimid (lenalidomide) after March 2022. Revlimid sales are expected to drop from US$ 12.9 billion to just US$ 2.06 billion in 2026. BMS posted US$ 46.4 billion in global revenues, a nine percent increase from US$ 42.5 billion reported in 2020. In immuno-oncology, Opdivo brought in US$ 7.52 billion in sales, while Yervoy drew in sales of US$ 2 billion (an increase of 20 percent). J&J’s pharma division brought in US$ 52.1 billion in revenues last year, an increase of 14 percent over its revenues of US$ 45.6 billion posted in 2020. Drugs like Darzalex (for multiple myeloma), Stelara and its Covid-19 vaccine brought in growth during 2021, helping J&J move up from number five to the number three slot. J&J’s Covid-19 vaccine brought in US$ 2.4 billion in sales.  View Our Interactive Dashboard on Top Drugs by Sales in 2021 (Free Excel Available) GSK bags approval for shingles vaccine; Takeda suffers setbacks GlaxoSmithKline (GSK) slipped four places — from number three in 2020 to number seven in 2021. Though GSK did not have a drug in the top 10, sales of GSK and Vir Biotechnology’s Covid-19 antibody treatment sotrovimab helped produce a seven percent increase in its 2021 revenue. The British drugmaker also bagged a critical FDA approval — its vaccine to prevent shingles (herpes zoster), Shingrix, bagged the agency’s nod in July. GSK hopes to double the sales of Shingrix by 2026.  GSK is also undergoing a major transformation, and plans to demerge its consumer health unit this year. The unit generated revenues of £9.6 billion (US$ 13 billion) last year, and GSK sees the demerger as a necessary step to fuel growth through the development of new vaccines and specialty medicines. Sanofi managed to retain its ninth slot, even as its global turnover increased from US$ 39.3 billion (Euro 36.04 billion) to US$ 41.6 billion (Euro 37.76 billion). It snapped up Kymab, Tidal Therapeutics, Translate Bio, Kadmon Holdings, Origimm Biotechnology and Amunix in deals that bolstered its presence in immunology, immuno-oncology and vaccines. Dealmaking is on the French drugmaker’s menu for 2022 and beyond, Sanofi’s CFO said at this year’s virtual JP Morgan Healthcare Conference. AstraZeneca’s global revenues grew from US$ 26.6 billion in 2020 to US$ 37.4 billion in 2021. However, its rank fell from nine in 2020 to 10 in 2021.  AstraZeneca wrapped up the US$ 39 billion acquisition of Alexion in July 2021. Alexion’s rare disease franchise—led by C5 inhibitors Soliris and Ultomiris—added an extra US$ 3.1 billion to Astra’s top line last year. Takeda suffered several clinical and regulatory setbacks in 2021, which it labeled as an “inflection year.” For Gilead, sales of its Covid-19 antiviral Veklury brought in US$ 5.6 billion last year, helping its revenues grow by 11 percent.  View Our Interactive Dashboard on Top Drugs by Sales in 2021 (Free Excel Available) Our view If anything, the pandemic has taught us that change is the only constant. It has also taught us that products can become blockbusters in a matter of a few months. The industry landscape continues to change. On the one hand, we are seeing people scrambling to get Covid vaccines and booster shots, on the other hand, the FDA has limited the use of monoclonal antibodies, such as Eli Lilly’s bamlanivimab and etesevimab and Regeneron’s REGEN-COV (casirivimab and imdevimab), in treating Covid caused by the Omicron variant. The FDA has also pulled the authorization granted to GSK and Vir Biotechnology’s antibody therapy this month, citing data that suggested it was unlikely to be effective against the dominant Omicron sub-variant. And last week, there was news that demand for Pfizer’s antiviral pill Paxlovid has remained unexpectedly low. The supply of Paxlovid, which reduced hospitalizations or deaths in high-risk patients by around 90 percent in a clinical trial, has far outstripped demand in many countries like the US, the UK and South Korea. Though Pfizer is hopeful of crossing US$ 100 billion in revenue this year, much depends on how the pandemic pans out and what new research has to say about the novel coronavirus. A lot will change once the pandemic becomes endemic. The first four months of 2022 tell us that vaccines like Comirnaty and Spikevax will continue to perform well. But two years down the line, our charts could look very different.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 8240

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2021-covid-vaccines-pills-cause-churn-in-list

    #PharmaFlow by PHARMACOMPASS
    28 Apr 2022
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California
    Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California

    11 Apr 2024

    // Ayisha Sharma ENDPTS

    https://endpts.com/sanofi-axes-100-staffers-in-california-home-to-amunix-which-it-bought-in-2021/

    Ayisha Sharma ENDPTS
    11 Apr 2024
    Share Share
    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
    Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors

    23 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/23/2251610/0/en/Amunix-Appoints-Industry-Veteran-Frank-Watanabe-to-its-Board-of-Directors.html

    GLOBENEWSWIRE
    23 Jun 2021
    Share Share
    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)
    Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR)

    13 Apr 2021

    // GLOBNEWSWIRE

    https://www.globenewswire.com/news-release/2021/04/12/2208186/0/en/Amunix-Presents-Preclinical-Data-at-American-Academy-of-Cancer-Research-AACR-Annual-Meeting-from-Lead-Program-AMX-818-Demonstrating-Robust-Efficacy-in-HER2-Tumor-Models-and-Enhance.html

    GLOBNEWSWIRE
    13 Apr 2021
    Share Share
    Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline
    Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline

    04 Mar 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/03/04/2187044/0/en/Amunix-Raises-117-Million-Series-B-Financing-to-Fund-its-Oncology-Pipeline.html

    GLOBENEWSWIRE
    04 Mar 2021
    Share Share
    Amunix scores $117M to fuel T-cell engagers, cytokines
    Amunix scores $117M to fuel T-cell engagers, cytokines

    04 Mar 2021

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/amunix-scores-117m-to-fuel-t-cell-engagers-cytokines-for-solid-tumors#:~:text=Biotech-,Amunix%20scores%20%24117M%20to%20fuel%20T,engagers%2C%20cytokines%20for%20solid%20tumors&text=Exactly%20one%20year%20after%20Amunix,from%20the%20venture%20capital%20well.

    Amirah Al Idrus FIERCE BIOTECH
    04 Mar 2021
    Share Share
    ESMO: Amunix's T-cell engagers shrink solid tumors in animal models
    ESMO: Amunix's T-cell engagers shrink solid tumors in animal models

    17 Sep 2020

    // A. Weintraub FIERCE BIOTECH

    https://www.fiercebiotech.com/research/esmo-amunix-s-t-cell-engagers-shrink-solid-tumors-animal-models

    A. Weintraub FIERCE BIOTECH
    17 Sep 2020
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sanofi Completes Acquisition of Amunix

    Details:

    The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms.


    Lead Product(s): AMX-818

    Therapeutic Area: Oncology Brand Name: AMX-818

    Study Phase: IND EnablingProduct Type: Large molecule

    Sponsor: Sanofi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition February 08, 2022

    Amunix

    01

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMX-818

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Sanofi Completes Acquisition of Amunix

    Details : The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms.

    Brand Name : AMX-818

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    February 08, 2022

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sanofi to Acquire Amunix Immuno-Oncology Pipeline with Next Generation Conditionally Activated Biologics

    Details:

    Under the terms of the agreement, Sanofi will acquire Amunix with it's pipeline including it's lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology.


    Lead Product(s): AMX-818

    Therapeutic Area: Oncology Brand Name: AMX-818

    Study Phase: IND EnablingProduct Type: Large molecule

    Sponsor: Sanofi

    Deal Size: $1,225.0 million Upfront Cash: $1,000.0 million

    Deal Type: Acquisition December 21, 2021

    Amunix

    02

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMX-818

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Sanofi

    Deal Size : $1,225.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Sanofi to Acquire Amunix Immuno-Oncology Pipeline with Next Generation Conditionally Activated Bio...

    Details : Under the terms of the agreement, Sanofi will acquire Amunix with it's pipeline including it's lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therap...

    Brand Name : AMX-818

    Molecule Type : Large molecule

    Upfront Cash : $1,000.0 million

    December 21, 2021

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

    Details:

    AMX-818, a protease-activated T cell engager targeting HER2 with potent T Cell activation, proteolytic cleavage and efficacy in Xenograft tumors.


    Lead Product(s): AMX-818

    Therapeutic Area: Oncology Brand Name: AMX-818

    Study Phase: IND EnablingProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 07, 2021

    Amunix

    03

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMX-818

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Confere...

    Details : AMX-818, a protease-activated T cell engager targeting HER2 with potent T Cell activation, proteolytic cleavage and efficacy in Xenograft tumors.

    Brand Name : AMX-818

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    October 07, 2021

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II

    Details:

    Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors.


    Lead Product(s): AMX-818

    Therapeutic Area: Oncology Brand Name: AMX-818

    Study Phase: IND EnablingProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 22, 2020

    Amunix

    04

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMX-818

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annu...

    Details : Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors.

    Brand Name : AMX-818

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    June 22, 2020

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Amunix Raises $73 Million in Series A Financing Led by Omega Funds

    Details:

    Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.


    Lead Product(s): AMX-818

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: IND EnablingProduct Type: Cell and Gene therapy

    Sponsor: Omega Funds

    Deal Size: $73.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing March 04, 2020

    Amunix

    05

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMX-818

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Omega Funds

    Deal Size : $73.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Amunix Raises $73 Million in Series A Financing Led by Omega Funds

    Details : Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.

    Brand Name : Undisclosed

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    March 04, 2020

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

    Details:

    This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.


    Lead Product(s): Polypeptides

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Peptide

    Sponsor: F. Hoffmann-La Roche

    Deal Size: $1,540.0 million Upfront Cash: $40.0 million

    Deal Type: Licensing Agreement January 10, 2020

    Amunix

    06

    Amunix

    U.S.A
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Polypeptides

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : F. Hoffmann-La Roche

    Deal Size : $1,540.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therap...

    Details : This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.

    Brand Name : Undisclosed

    Molecule Type : Peptide

    Upfront Cash : $40.0 million

    January 10, 2020

    Amunix

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search